- Business Wire•5 days ago
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced that it will host a conference call and live audio webcast to discuss third quarter financial and business results on Thursday, November 3.
- Business Wire•last monthTherapeuticsMD Announces Multiple Presentations Related to Yuvvexy™ (TX-004HR) at Two Upcoming Medical Conferences
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the schedule of nine posters and oral presentations at upcoming medical conferences related to Yuvvexy, the conditionally-approved trade name for TX-004HR, an investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse , ...
- Business Wire•last monthTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy™ (TX-004HR)
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.S.
TherapeuticsMD, Inc. (TXMD)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||6.21 x 1600|
|Ask||6.22 x 7700|
|Day's Range||6.09 - 6.33|
|52wk Range||5.69 - 11.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-14.68|
|Avg Vol (3m)||1,361,166|
|Dividend & Yield||N/A (N/A)|